A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8846-8853

  Planagumà, Jesús ^a   Díaz Fuertes, María ^a   Gil Moreno, Antonio ^b,e   Abal, Miguel ^a   Monge, Marta ^a   García, Angel ^a   Baró, Teresa ^c   Thomson, Timothy M ^a,d   Xercavins, Jordi ^b,e   Alameda, Francesc ^c,e   Reventós, Jaume ^a,b,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC MODEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RUNX1 AML1 GENE; UNINDEXED SEQUENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 10844236511     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2066     Document Type: Article

References (37)

1. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335;640-9.
2. Esteller M, Xercavins J, Reventos J. Advances in the molecular genetics of endometrial cancer [review]. Oncol Rep 1999;6:1377-82.
3. Caduff RF, Svoboda-Neumann SM, Johnston CM, Bartos RE, Frank TS. Molecular analysis in endometrial cancer. Verb Dtsch Ges Pathol 1997;81:219-27.
4. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus; a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002;9:145-84.
5. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-89.
6. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
7. Catasus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-4.
8. Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003;21:4364-70.
9. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
10. Matsushima-Nishiu M, Unoki M, Ono K, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 2001;61:3741-9.
11. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventes J. The clinico-pathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997;33:1572-7.
12. Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J, K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-9.
13. Schlosshauer PW, Pirog EC, Levine RL, Ellenson LH. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 2000;13:1066-71.
14. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
15. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer (Phila.) 2000;88:814-24.
16. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003;9:27-31.
17. Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol 1997;28:607-12.
18. Hedrick, L. Endometrial cancer. New York: McGraw-Hill; 1998. p. 621-9.
19. Sambrok J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Vol 2. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
20. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendoraetrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003;63:5697-702.
21. Perry C, Eldor A, Soreq H. Runx1/AML1 in leukemia: disrupted association with diverse protein partners. Leuk Res 2002;26:221-8.
22. Kurokawa M, Hirai H. Role of AML1/Runx1 in the pathogenesis of hematological malignancies. Cancer Sci 2003;94:841-6.
23. Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Investig 2003;21:105-36.
24. Bernardin F, Friedman AD. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene 2002;21:3247-52.
25. Imai O, Kurokawa M, Izutsu K, et al. Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome. Leuk Lymphoma 2002;43:617-21.
26. Kurokawa M, Tanaka T, Tanaka K, et al. Overexpression of the AML1 protooncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 1996;12:883-92.
27. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
28. Kagoshima H, Shigesada K, Satake M, et al. The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet 1993;9:338-41.
29. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993;13:6336-45.
30. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998;17;2994-3004.
31. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 2000;275:651-6.
32. Harrington KS, Javed A, Drissi H, et al. Transcription factors RUNX1/AML1 and RUNX2/Cbfa1 dynamically associate with stationary subnuclear domains. J Cell Sci 2002;115:4167-76.
33. Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol 1999;19:3635-44.
34. Taniuchi I, Littman DR. Epigenetic gene silencing by Runx proteins. Oncogene 2004;23:4341-5.
35. Durst KL, Hiebert SW. Role of RUNX family members in transcriptional repression and gene silencing. Oncogene 2004;23:4220-4.
36. Liu YN, Kang BB, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells. Oncogene 2004;23:278-88.
37. Puig-Kroger A, Lopez-Rodriguez C, Relloso M, et al. Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter. J Biol Chem 2000;275:28507-12.